Lorazepam injection vials recalled for elevated impurities and degradation
Hikma Pharmaceuticals is recalling 1,352,475 vials of Lorazepam Injection due to failed quality tests showing elevated degradation compounds. Affected lots were distributed nationwide and in Puerto Rico.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall affecting a large quantity of injectable medication due to confirmed quality failure with elevated degradation products. Although no illnesses or injuries have been reported, degradation in a benzodiazepine injectable product presents a risk-of-harm to patients.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling Lorazepam Injection, USP, 2mg/mL vials (NDC 0641-6044-01 and -25) manufactured by West-Ward. A total of 1,352,475 vials are affected due to failed quality specifications.
During retained sample testing, out-of-specification results were found for total related compounds. Specifically, Related Compound-C was elevated beyond acceptable limits, indicating chemical degradation of the injectable product.
The affected lots (070086 and 070128, expiring July 2023) were distributed nationwide in the United States and Puerto Rico.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug — Benzodiazepine Injectable
- Hazard
- impurities
- degradation
- quality-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 070086
- 070128
- Exp. 07/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LORAZEPAM
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled nationwide for manufacturing specification failures
FDA (Drugs) · 2022-08-17
- HighLorazepam Injection Recalled for Out-of-Specification Impurities and Degradation
FDA (Drugs) · 2022-08-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27